Alto Neuroscience, Inc.
ANRO
$27.04
$1.746.88%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 35.28% | 14.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 59.12% | 14.07% | |||
| Operating Income | -59.12% | -14.07% | |||
| Income Before Tax | -62.14% | -14.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -62.14% | -14.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -62.14% | -14.11% | |||
| EBIT | -59.12% | -14.07% | |||
| EBITDA | -59.51% | -14.28% | |||
| EPS Basic | -68.48% | 9.52% | |||
| Normalized Basic EPS | -68.47% | 9.51% | |||
| EPS Diluted | -68.48% | 9.52% | |||
| Normalized Diluted EPS | -68.47% | 9.51% | |||
| Average Basic Shares Outstanding | -3.77% | 26.12% | |||
| Average Diluted Shares Outstanding | -3.77% | 26.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||